

Online Supplementary Appendix

Table of Contents

Appendix S1. Additional Methodologic details

Table S1. Weighting of adverse events

Table S2. Hemorrhagic events and event rates per total patient years in a given INR range

Table S3. Thrombotic events and event rates per total patient years in a given INR range

Table S4. Anticoagulation and Antiplatelet Protocols

Figure S1. Hemorrhagic event rates per INR range multiplied by expected 30 day mortality rates for each adverse event

Figure S2. Thrombotic event rates per INR range multiplied by expected 30 day mortality rates for each adverse event

Figure S3. Optimal INR ranges with varying weights of thrombotic and hemorrhagic events

Appendix S1 –

Event rates per patient-year were computed to account for differences in observable time among INR ranges. A Poisson model with offset equal to the log INR years, as determined by the natural log of the time spent in INR range, was used to develop estimates, confidence intervals, and compare ranges. No overdispersion was identified. Poisson models were developed using generalized estimating equations to account for correlated data corresponding to patients providing data towards multiple INR ranges.

Table S1 –

| | Internal data deaths/patient month | Literature Review deaths/patient month | Value utilized in weighing scheme |
|-----------------------|--|--|--------------------------------------|
| Pump Thrombosis | 0.142 | 0.18(1) | 0.16 |
| GI Bleed | 0.008 | 0.01 (9) | 0.01 |
| Ischemic Stroke | 0.113 | 0.10 (4,5) | 0.11 |
| Hemorrhagic Stroke | 0.58 | 0.40 (6) | 0.49 |

GI = gastrointestinal

Table S2 –

| INR range | Patient years | Events Per INR range | | | Event rate per 10 patient-years | | |
|-------------|---------------|----------------------|-----|-------|---------------------------------|------|-------|
| | | ICH | GIB | Total | ICH | GIB | Total |
| 0 – 1.49 | 40.32 | 0 | 3 | 3 | 0 | 0.7 | 0.7 |
| 1.50 – 1.99 | 110.74 | 1 | 10 | 11 | 0.1 | 0.9 | 1.0 |
| 2.00 – 2.49 | 101.26 | 1 | 20 | 21 | 0.1 | 2.0 | 2.1 |
| 2.50 – 2.99 | 47.53 | 2 | 5 | 7 | 0.4 | 1.1 | 1.5 |
| 3.00 – 3.49 | 15.04 | 2 | 4 | 6 | 1.3 | 2.7 | 4.0 |
| ≥ 3.5 | 9.86 | 3 | 11 | 14 | 3.0 | 11.2 | 14.2 |

ICH = intracranial hemorrhage; GIB = gastrointestinal bleeding.

Table S3 –

| INR range | Patient years | Event Per INR range | | | Event rate per 10 patient-years | | |
|-------------|---------------|---------------------|--------|-------|---------------------------------|--------|-------|
| | | PT | Isc St | Total | PT | Isc St | Total |
| 0 – 1.49 | 40.31 | 9 | 7 | 16 | 2.2 | 1.7 | 4.0 |
| 1.50 – 1.99 | 111.39 | 13 | 4 | 17 | 1.2 | 0.4 | 1.5 |
| 2.00 – 2.49 | 101.76 | 9 | 3 | 12 | 0.9 | 0.3 | 1.2 |
| 2.50 – 2.99 | 47.80 | 0 | 0 | 0 | 0 | 0 | 0 |
| 3.00 – 3.49 | 15.22 | 1 | 0 | 1 | 0.7 | 0 | 0.7 |
| ≥ 3.5 | 9.95 | 0 | 0 | 0 | 0 | 0 | 0 |


PT = pump thrombosis; Isc St = ischemic stroke.

Table S4 - Anticoagulation and Antiplatelet Protocols

| | 2004 through 2008 | 2009 through 2011 | 2012 through Current |
|--|-------------------|-------------------|----------------------|
| Intravenous anticoagulation – bridge to warfarin | Yes | Occasional | Yes |
| INR goal | 2.0-2.5 | 1.5-2.0 | 2.0-3.0 |
| Aspirin dose (mg) | 81 or 325 | 81 or 325 | 325 |
| Bivalirudin | Yes | Yes | Selective (HIT) |


INR = international normalized ratio; HIT = heparin induced thrombocytopenia

Figure S1 –




Hemorrhagic event rates per INR range multiplied by expected 30 day mortality rates for each adverse event

Figure S2 –



Thrombotic event rates per INR range multiplied by expected 30 day mortality rates for each adverse event

Figure S3-



Optimal INR ranges with varying weights of thrombotic and hemorrhagic events